Treatment of cardiovascular and renal risk factors in the diabetic hypertensive

Hypertension

Volumn 40, Issue 6, 2002, Pages 781-788

  Sowers, James R ^a   Haffner, Steven ^b  

^a SUNY Downstate Medical Center   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Aspirin; Diabetes; Hyperglycemia; Lipids

Indexed keywords

AMLODIPINE; GLIPIZIDE; HYDROCHLOROTHIAZIDE; LOW DENSITY LIPOPROTEIN; SULFONYLUREA;

ADULT; ANAMNESIS; ARTICLE; BLOOD PRESSURE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC HYPERTENSION; DIALYSIS; FAMILY HISTORY; FEMALE; GENERAL PRACTITIONER; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; LABORATORY TEST; LIPID BLOOD LEVEL; MEDICAL RECORD; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETINOPATHY; RISK FACTOR;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; EDEMA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 0036899291     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000042097.39655.B7     Document Type: Article

References (59)

1. Haffner SM, Lehto S, Rönnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infraction. N Engl J Med. 1998;339:229-234.
2. Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med. 2000;342:1040-1042.
3. Sowers JR, Epstein M, Frolich ED. Diabetes, hypertension and cardiovascular disease: An update. Hypertension. 2001;37:1053-1059.
4. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care. 1998;21:69-75.
5. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141-1147.
6. Lehto S, Rönnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke. 1996; 27:63-68.
7. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Steward D, Pinkett T, Ghali JK, Wilson AC. Diabetes mellitus: A predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLV) Trials and Registry. Am J Cardiol. 1996;77:1017-1020.
8. Gustafsson I, Hildebrundt P. Early failure of the diabetic heart. Diabetes Care. 2001;24:3-4.
9. Bakris GL, Williams M, Dworkin L, Epstein M, Tota R, Tuttle K, Hsueh D, Sowers JR. Preserving renal function in adults with hypertension and diabetes: A consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
10. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S, for HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
11. Miettinen H, Haffner SM, Lehto S, Rönnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke. 1996;27:2033-2039.
12. Intensive blood-glucose controls with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;325:837-853.
13. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;25(suppl 1):S33-S49.
14. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, for Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344:1343-1350.
15. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet: DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3-10.
16. Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller ER 3rd, Lin PH, Karanja NM, Most-Windhauser MM, Moore TJ, Swain JF, Bales CW, Proschan MA, for the DASH Research Group. Effects on blood lipids of a blood pressure lowering diet: The Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr. 2001;74:80-89.
17. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
18. Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, Curb JD. Glucose Intolerance and 23-year Risk of Coronary Heart Disease and Total Mortality: The Honolulu Heart Program Diabetes Care. 1999; 22:1262-1265.
19. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
20. Coronary heart disease risk assessment in diabetes mellitus: A comparison of PROCAM and Framingham risk assessment functions. Diabet Med. 2001;18:355-359.
21. Assman G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation. 2002;105:310-315.
22. Moss SE, Klein R, Klein BEK, Meurer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med. 1994;154:2473-2479.
23. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43:960-967.
24. Andersson DKG, Svardsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care. 1995;18:534-543.
25. Gall MA, Borch-Johnson K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes. 1995;44:1303-1309.
26. Hadden DR, Patterson CC, Atkinson AB, Kennedy L, Bell PM, McCance DR, Weaver JA. Macrovascular disease and hyperglycemia: 10-year survival analysis in type 2 diabetes mellitus: The Belfast Diet Study. Diabet Med. 1997;14:663-672.
27. Risk factors for coronary artery disease in non-insulin dependent diabetes: United Kingdom Prospective Diabetes Study Group. BMJ. 1998; 316:823-828.
28. Wei M, Gaskell SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality: The San Antonio Heart Study. Diabetes Care. 1998;21:1167-1172.
29. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
30. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65.
31. Lawson M, Gerstein HC, Tsui E, Zinman B. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes: A systematic review and meta-analysis. Diabetes Care. 1999;22: B35-B39.
32. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: United Kingdom Prospective Diabetes Study Group. BMJ. 1998;317:720-726.
33. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Manninen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M. Model of complications of NIDDM: Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997;20:735-744.
34. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care. 1997;20:1847-1853.
35. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2002;25(suppl 1):S71-S73.
36. Sowers JR, Reed J. Clinical advisory treatment of hypertension and diabetes. J Clin Hypertens. 2000 1999;2:132-133.
37. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Westerling S, for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
38. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R, for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium channel blockers in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684.
39. Niskanen L, Hedner T, Hansson L, for the CAPP study group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/βblocker-based treatment regimen: A subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24:2091-2096.
40. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes: Results of the HOPE study and Micro-HOPE substudy. Lancet. 2000;355:253-259.
41. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
42. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
43. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345:851-860.
44. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440-1444.
45. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:1004-1010.
46. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001;135:447-459.
47. Lipid (Long-Term Intervention with Pravastatin in Ischemic Disease) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
48. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyorala K. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analysis in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999;159:2661-2667.
49. Sacks FM, Tonkin AM, Cranen T, Pfeffer MA, Shepard J, Keuh A, Furberg CD, Braunwald E. Coronary heart disease in patients with low LDL cholesterol: Benefits of pravastatin in diabetes and enhanced role for HDL cholesterol and triglycerides as risk factors. Circulation. 2002;105: 1424-1428.
50. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomized placebo-controlled trial. Lancet. 2002;360:7-22.
51. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects of statins: Lipid reduction and beyond. J Clin Endocrinol Metab. 2002; 87:1451-1458.
52. Fagan TC, Sowers J. Type 2 diabetes mellitus: Greater cardiovascular risks and greater benefits of therapy. Arch Intern Med. 1999;24:159: 1033-1034.
53. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J. 2002;195:1-4.
54. Sowers JR. Hypertension, angiotensin II, and oxidative stress. N Engl J Med. 2002;346:1999-2001.
55. Davis TM, Millns H, Stratton IM, Holman RR, Turner RC. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med. 1999;159:1097-1103.
56. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. Primary prevention of ischemic stroke: A statement for healthcare professionals from the stroke council of the American Heart Association. Circulation. 2001;103:163-182.
57. American Diabetes Association. Aspirin therapy in diabetes (position statement). Diabetes Care. 2001;24:S62-S63.
58. Shahar E, Folsom AR, Romm FJ, Bisgard KM, Metcalf PA, Crum L, McGovern PG, Hutchinson RG, Heiss G. Patterns of aspirin use in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 1996;131:915-922.
59. McFarlane SI, Jacober SJ, Winer N, Sowers JR. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care. 2002;25:718-723.